Pluristem Therapeutics Inc (NASDAQ:PSTI) Institutional Investor Sentiment Analysis

July 14, 2018 - By Marguerite Chambers

Pluristem Therapeutics Inc. (NASDAQ:PSTI) Logo

Sentiment for Pluristem Therapeutics Inc (NASDAQ:PSTI)

Pluristem Therapeutics Inc (NASDAQ:PSTI) institutional sentiment decreased to 0.92 in Q1 2018. Its down -0.75, from 1.67 in 2017Q4. The ratio dived, as 12 investment managers started new or increased stock positions, while 13 sold and decreased their equity positions in Pluristem Therapeutics Inc. The investment managers in our partner’s database now own: 3.29 million shares, down from 3.73 million shares in 2017Q4. Also, the number of investment managers holding Pluristem Therapeutics Inc in their top 10 stock positions was flat from 0 to 0 for the same number . Sold All: 8 Reduced: 5 Increased: 5 New Position: 7.

Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics firm in Israel. The company has market cap of $144.13 million. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. It currently has negative earnings. The firm develops PLacental eXpanded cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for femoral neck fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases.

The stock increased 4.00% or $0.05 during the last trading session, reaching $1.3. About 403,091 shares traded. Pluristem Therapeutics Inc. (NASDAQ:PSTI) has declined 4.29% since July 14, 2017 and is downtrending. It has underperformed by 16.86% the S&P500.

Analysts await Pluristem Therapeutics Inc. (NASDAQ:PSTI) to report earnings on September, 6. They expect $-0.09 earnings per share, down 28.57 % or $0.02 from last year’s $-0.07 per share. After $-0.01 actual earnings per share reported by Pluristem Therapeutics Inc. for the previous quarter, Wall Street now forecasts 800.00 % negative EPS growth.

Menora Mivtachim Holdings Ltd. holds 0.04% of its portfolio in Pluristem Therapeutics Inc. for 1.00 million shares. Heritage Investors Management Corp owns 74,878 shares or 0.01% of their US portfolio. Moreover, Psagot Investment House Ltd. has 0.01% invested in the company for 125,867 shares. The New York-based A.R.T. Advisors Llc has invested 0% in the stock. Atwood & Palmer Inc, a Missouri-based fund reported 33 shares.

More recent Pluristem Therapeutics Inc. (NASDAQ:PSTI) news were published by: Globenewswire.com which released: “Pluristem and Fukushima University Report Positive Data: PLX-R18 Increases Survival Rates and Mitigates Severe …” on June 25, 2018. Also Globenewswire.com published the news titled: “Pluristem Signs Collaboration Agreement With Thermo Fisher Scientific” on July 09, 2018. Prnewswire.com‘s news article titled: “Corporate Biotech Executive Mark Germain Joins BiondVax’s Board of Directors” with publication date: June 28, 2018 was also an interesting one.

Pluristem Therapeutics Inc. (NASDAQ:PSTI) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>